Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
1997 1
1998 1
2000 1
2003 1
2007 2
2008 1
2009 3
2010 4
2011 23
2012 15
2013 25
2014 29
2015 17
2016 6
2017 10
2018 5
2019 2
2020 4
2021 2
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24336338

132 results

Results by year

Filters applied: . Clear all
Page 1
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T. Izumi K, et al. PLoS One. 2015 Dec 23;10(12):e0145468. doi: 10.1371/journal.pone.0145468. eCollection 2015. PLoS One. 2015. PMID: 26698858 Free PMC article. Clinical Trial.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Genovese MC, et al. Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940. Arthritis Rheum. 2008. PMID: 18821691 Free article. Clinical Trial.
[The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q, Zhao Y, Bao CD, Li XF, Huang F, Zhu P, Li ZG, Gu JR, Zhang ZY, Zhao DB, Zhao SL, Jiang QD, Tian J, Zhang FC. Shi Q, et al. Zhonghua Nei Ke Za Zhi. 2013 Apr;52(4):323-9. Zhonghua Nei Ke Za Zhi. 2013. PMID: 23925361 Clinical Trial. Chinese.
Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.
Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, Yabe Y, Kato T, Terabe K, Fukaya N, Tsuchiya H, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Ishiguro N. Kojima T, et al. Mod Rheumatol. 2012 Jun;22(3):370-5. doi: 10.1007/s10165-011-0528-2. Epub 2011 Sep 20. Mod Rheumatol. 2012. PMID: 21931942
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Nishimoto N, et al. Mod Rheumatol. 2014 Jan;24(1):17-25. doi: 10.3109/14397595.2013.854079. Mod Rheumatol. 2014. PMID: 24261754
132 results